Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
出版年份 2016 全文链接
标题
Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
作者
关键词
Hypoglycemia, Meta-analysis, Insulin, HbA1c, Diabetes mellitus, Network analysis, Glucagon, Randomized controlled trials
出版物
PLoS One
Volume 11, Issue 5, Pages e0154206
出版商
Public Library of Science (PLoS)
发表日期
2016-05-10
DOI
10.1371/journal.pone.0154206
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Emerging New Therapies for the Treatment of Type 2 Diabetes Mellitus: Glucagon-like Peptide-1 Receptor Agonists
- (2015) Christopher A. Lindamood et al. CLINICAL THERAPEUTICS
- Association Between Hypoglycemia and Fall-Related Events in Type 2 Diabetes Mellitus: Analysis of a U.S. Commercial Database
- (2015) Sumesh Kachroo et al. Journal of Managed Care & Specialty Pharmacy
- A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus
- (2014) Yutaka Seino et al. CURRENT MEDICAL RESEARCH AND OPINION
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
- (2014) Michael Nauck et al. DIABETES CARE
- Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5
- (2014) P. D. Home et al. DIABETES OBESITY & METABOLISM
- Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)
- (2014) Julio Rosenstock et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
- (2014) Kathleen M Dungan et al. LANCET
- Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis
- (2014) Conrad Eng et al. LANCET
- Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: Data from the Italian AIFA Anti-diabetics Monitoring Registry
- (2014) S. Montilla et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
- (2014) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial
- (2014) Michaela Diamant et al. Lancet Diabetes & Endocrinology
- GLP-1 receptor agonists: a review of head-to-head clinical studies
- (2014) Jennifer M. Trujillo et al. Therapeutic Advances in Endocrinology and Metabolism
- GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician?
- (2013) André J. Scheen ANNALES D ENDOCRINOLOGIE
- Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes
- (2013) John B. Buse et al. ANNALS OF INTERNAL MEDICINE
- Predictors of medication adherence in patients with type 2 diabetes mellitus
- (2013) Suellen M. Curkendall et al. CURRENT MEDICAL RESEARCH AND OPINION
- Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
- (2013) Robert R. Henry et al. DIABETES CARE
- Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)
- (2013) Bo Ahrén et al. DIABETES CARE
- Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin
- (2013) Matthew C. Riddle et al. DIABETES CARE
- Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine
- (2013) Matthew C. Riddle et al. DIABETES CARE
- Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)
- (2013) M. Pinget et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial
- (2013) B. Charbonnel et al. DIABETOLOGIA
- Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study)
- (2013) Priscilla Hollander et al. Obesity
- Efficacy and Safety Profile of Exenatide Once Weekly Compared With Insulin Once Daily in Japanese Patients With Type 2 Diabetes Treated With Oral Antidiabetes Drug(s): Results From a 26-Week, Randomized, Open-Label, Parallel-Group, Multicenter, Noninferiority Study
- (2012) Nobuya Inagaki et al. CLINICAL THERAPEUTICS
- Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24 Weeks of Treatment: Results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1)
- (2012) I. Raz et al. DIABETES CARE
- Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks
- (2012) M. Diamant et al. DIABETES CARE
- Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas
- (2012) M. Davies et al. DIABETES CARE
- Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
- (2012) V. A. Fonseca et al. DIABETES CARE
- The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial
- (2012) J. Rosenstock et al. DIABETES CARE
- Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6)
- (2012) R. E. Pratley et al. DIABETES OBESITY & METABOLISM
- Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
- (2012) Y. Seino et al. DIABETES OBESITY & METABOLISM
- Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: A pairwise and network meta-analysis
- (2012) Feng Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial
- (2012) M. Nauck et al. DIABETIC MEDICINE
- Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes
- (2012) G. Derosa et al. DIABETIC MEDICINE
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
- (2012) John B Buse et al. LANCET
- Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus
- (2012) Linong Ji et al. Journal of Diabetes Investigation
- Automating network meta-analysis
- (2012) Gert van Valkenhoef et al. Research Synthesis Methods
- Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial)
- (2012) Richard M. Bergenstal et al. Diabetes Therapy
- Loss of Inverse Relationship Between Pulsatile Insulin and Glucagon Secretion in Patients With Type 2 Diabetes
- (2011) B. A. Menge et al. DIABETES
- Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes: A randomized 26-week study on glycemic control and hypoglycemia
- (2011) B. Gallwitz et al. DIABETES CARE
- Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study
- (2011) D. Russell-Jones et al. DIABETES CARE
- The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study
- (2011) G. E. Umpierrez et al. DIABETES OBESITY & METABOLISM
- One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
- (2011) R. Pratley et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
- (2011) Thomas Blevins et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants
- (2011) Goodarz Danaei et al. LANCET
- Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes
- (2010) Caroline M. Apovian et al. AMERICAN JOURNAL OF MEDICINE
- Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes
- (2010) Y. Seino et al. CURRENT MEDICAL RESEARCH AND OPINION
- Pathogenesis of Fasting and Postprandial Hyperglycemia in Type 2 Diabetes: Implications for Therapy
- (2010) R. A. Rizza DIABETES
- Effects of Exenatide Plus Rosiglitazone on -Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin
- (2010) R. A. DeFronzo et al. DIABETES CARE
- DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
- (2010) J. B. Buse et al. DIABETES CARE
- A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin
- (2010) J. Liutkus et al. DIABETES OBESITY & METABOLISM
- Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl
- (2010) W. Yang et al. DIABETES OBESITY & METABOLISM
- Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
- (2010) A. Garber et al. DIABETES OBESITY & METABOLISM
- Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study1,2
- (2010) R. Ratner et al. DIABETIC MEDICINE
- Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
- (2010) R. E. Ratner et al. DIABETIC MEDICINE
- Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus
- (2010) Baptist Gallwitz DRUG SAFETY
- Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
- (2010) Georgia Salanti et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
- (2010) David Moher et al. International Journal of Surgery
- Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks
- (2010) Takashi Kadowaki et al. Journal of Diabetes Investigation
- Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus
- (2009) Joshua J Neumiller et al. ANNALS OF PHARMACOTHERAPY
- Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea
- (2009) Richard Bergenstal et al. CURRENT MEDICAL RESEARCH AND OPINION
- Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing
- (2009) J. Rosenstock et al. DIABETES CARE
- Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study
- (2009) M. A. Nauck et al. DIABETES CARE
- One-Year Treatment With Exenatide Improves -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial
- (2009) M. C. Bunck et al. DIABETES CARE
- Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study
- (2009) M. J. Davies et al. DIABETES OBESITY & METABOLISM
- Glycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances
- (2009) K. Khunti et al. DIABETES OBESITY & METABOLISM
- Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
- (2009) M. Marre et al. DIABETIC MEDICINE
- Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
- (2009) D. Russell-Jones et al. DIABETOLOGIA
- Exenatide Exhibits Dose-Dependent Effects on Glycemic Control over 12 Weeks in Japanese Patients with Suboptimally Controlled Type 2 Diabetes
- (2009) Takashi KADOWAKI et al. ENDOCRINE JOURNAL
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes
- (2009) Kazuya IWAMOTO et al. ENDOCRINE JOURNAL
- Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials
- (2009) Matteo Monami et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Insulin Glargine: a review 8 years after its introduction
- (2009) Stanislav Goykhman et al. EXPERT OPINION ON PHARMACOTHERAPY
- Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists
- (2009) K. B. Hansen et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- The Intersection of Safety and Adherence: New Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus
- (2009) Barbara J Zarowitz et al. PHARMACOTHERAPY
- Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study
- (2008) T MORETTO et al. CLINICAL THERAPEUTICS
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
- (2008) M. Nauck et al. DIABETES CARE
- Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes
- (2008) Y. Seino et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea
- (2008) Yan Gao et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus
- (2008) Estela Wajcberg et al. EXPERT OPINION ON PHARMACOTHERAPY
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started